Nanobiotix SA

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jan 2024 16:32:08 By Nasdaq GlobeNewswire

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

26 Dec 2023 02:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Dec 2023 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

04 Dec 2023 16:16:59 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

13 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

09 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Closing of Global Offering

07 Nov 2023 16:01:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

06 Nov 2023 02:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

02 Nov 2023 10:49:35 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

01 Nov 2023 18:32:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

23 Oct 2023 02:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Oct 2023 16:27:41 By Nasdaq GlobeNewswire

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

04 Oct 2023 16:30:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

29 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

28 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

26 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

19 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Sep 2023 16:15:00 By Nasdaq GlobeNewswire